Close

Optimer Pharma (OPTR) Reports Superior Performance from DIFICID Phase 3 vs. Oral Vancomycin

Go back to Optimer Pharma (OPTR) Reports Superior Performance from DIFICID Phase 3 vs. Oral Vancomycin
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) Delayed: 12.78 --0 (-0%)
Previous Close $12.78    52 Week High $16.80 
Open $12.78    52 Week Low $8.64 
Day High $12.78    P/E N/A 
Day Low $12.78    EPS $-1.75 
Volume 1,179,540